A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

Background:   Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.

Methods:   A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy.

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

Background: Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients.

Objective: To compare Sativex with placebo in relieving symptoms of spasticity due to MS.

Methods: A 15-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study in 337 subjects with MS spasticity not fully relieved with current anti-spasticity therapy.

[Granulomatous myopathy in patients with sarcoidosis and myasthenia gravis].

Granulomatous myopathies are extremely rare. The finding of epithelioid granulomas in muscle biopsy indicates mostly an involvement of the skeletal muscle in systemic sarcoidosis. In this report we provide description of five patients with previously diagnosed sarcoidosis (pulmonary or cutaneous), in which a clinically significant muscle weakness developed.

[Activation tests in the diagnosis of myasthenia gravis using repetitive stimulation].

145 patients with confirmed myasthenia gravis were examined by repetitive stimulation at a frequency of 2-3 s-1. A decrement of the proximal muscles at rest was demonstrated in 116 (80%) of the patients and the deltoid muscle was most sensitive. In 29 patients without a significant decrement at rest activation test were supplemented.

[Recurrent hemorrhage into the mesencephalon].

The author described the case of a 19-year-old man, normotensive, who developed after a blunt injury of the head haemorrhage into the left part of the mesencephalon with the symptomatology Weber's stem syndrome. Manifestation of focal symptoms was recorded three days after the injury. The cerebrospinal fluid examined on the fourth day was normal, cerebrospinal fluid one week later was blood stained.